KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Leases (2020 - 2021)

Recursion Pharmaceuticals' Capital Leases history spans 2 years, with the latest figure at $9.3 million for Q4 2021.

  • For Q4 2021, Capital Leases rose 244.87% year-over-year to $9.3 million; the TTM value through Dec 2021 reached $9.3 million, up 244.87%, while the annual FY2021 figure was $9.3 million, 244.87% up from the prior year.
  • Capital Leases reached $9.3 million in Q4 2021 per RXRX's latest filing, up from $3.5 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $9.3 million in Q4 2021 to a low of $2.4 million in Q2 2021.